PMID- 33133865
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 9
DP  - 2020 Sep 28
TI  - Glimepiride and Metformin Combinations in Diabetes Comorbidities and 
      Complications: Real-World Evidence.
PG  - e10700
LID - 10.7759/cureus.10700 [doi]
LID - e10700
AB  - Objective To evaluate the usage of various strengths of glimepiride and metformin 
      fixed-dose combinations in the management of type 2 diabetes mellitus (T2DM) 
      patients with comorbidities and complications. Methods A retrospective, 
      non-randomized, non-comparative, multi-centric real-world study included 
      T2DM patients (age > 18 years) taking glimepiride and metformin fixed-dose 
      combinations. Age, duration of diabetes, diabetes complications, comorbidities 
      (hypertension and dyslipidemia), dosage frequency, and concomitant medications 
      were analyzed from medical charts. Results A total of 4858 T2DM patients were 
      included, with a mean age of 52.67 years and males being predominant in the study 
      population (60.85%). The laboratory investigations showed a mean glycated 
      hemoglobin (HbA1c) of 7.5, low-density lipoprotein (LDL) cholesterol of 104.81 +/- 
      38.19 mg/dL, and serum creatinine of 0.88 +/- 0.26 mg/dL. Around 2055 (42.30%) T2DM 
      patients were hypertensive, and telmisartan alone and a telmisartan-based 
      combination were the drugs of choice for hypertension management. Similarly, 1073 
      (22.08%) T2DM patients were having dyslipidemia and were primarily managed with 
      rosuvastatin and its combination in 664 (62%) patients. Macrovascular 
      complications were observed in 339 (6.97%) T2DM patients, among which coronary 
      artery disease (CAD) had maximum prevalence, affecting 273 (5.61%) T2DM patients. 
      Microvascular complications were 1010 (20.79%) T2DM patients, among which 
      neuropathy had affected a maximum of 686 (14.12%) followed by retinopathy (2.34%) 
      and nephropathy (1.81%). Among the available 11 strengths, the glimepiride 2 mg 
      and metformin 500 mg combination were most widely prescribed in 1297 (26.69%), 
      followed by glimepiride 1 mg and metformin 500 mg in 1193 (24.57%) patients, and 
      the preferred dosage pattern was twice a daily in 2665 (54.85%) T2DM patients. An 
      age-wise prescription analysis showed that glimepiride and metformin combinations 
      were the preferred choice for the management of diabetes across all the age 
      groups. Conclusion The real-world evidence in the Indian clinical setting 
      indicates that glimepiride and metformin fixed-dose combinations are widely used 
      in the management in T2DM patients with comorbidities like hypertension, 
      dyslipidemia, and diabetes complications. Glimepiride and metformin fixed-dose 
      combinations are suitable for early as well as long-standing diabetes.
CI  - Copyright (c) 2020, Sahay et al.
FAU - Sahay, Rakesh Kumar
AU  - Sahay RK
AD  - Department of Endocrinology, Osmania Medical College, Hyderabad, IND.
FAU - Mittal, Vinod
AU  - Mittal V
AD  - Centre for Diabetes & Metabolic Diseases, Delhi Heart & Lung Institute, New 
      Delhi, IND.
FAU - Gopal, G Raja
AU  - Gopal GR
AD  - Department of Endocrinology and Diabetes, Sriridhi Endocrinology & Diabetes Super 
      Specialty Clinic, Kurnool, IND.
FAU - Kota, Sunil
AU  - Kota S
AD  - Department of Endocrinology, Endocare Hospital, Vijaywada, IND.
FAU - Goyal, Ghanshyam
AU  - Goyal G
AD  - Department of Endocrinology, S K Diabetes Research and Education Centre, Kolkata, 
      IND.
FAU - Abhyankar, Mahesh
AU  - Abhyankar M
AD  - Scientific Services, USV Private Limited, Mumbai, IND.
FAU - Revenkar, Santosh
AU  - Revenkar S
AD  - Scientific Services, USV Private Limited, Mumbai, IND.
LA  - eng
PT  - Journal Article
DEP - 20200928
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7594657
OTO - NOTNLM
OT  - durability
OT  - fixed dose combination
OT  - glimepiride
OT  - long standing
OT  - metformin
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
PMCR- 2020/09/28
CRDT- 2020/11/02 06:18
PHST- 2020/11/02 06:18 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
PHST- 2020/09/28 00:00 [pmc-release]
AID - 10.7759/cureus.10700 [doi]
PST - epublish
SO  - Cureus. 2020 Sep 28;12(9):e10700. doi: 10.7759/cureus.10700.